Suven Starts Key Depression Drug Trial

  Published 10 months ago

Suven Life Sciences begins Phase-2b trial of Ropanicant for depression, following promising Phase-2a safety and efficacy results.

  • Ropanicant targets α4β2 nAChR receptors, showing rapid antidepressant effects in earlier trials with a good safety profile.
  • Phase-2b trial is placebo-controlled, double-blinded, and conducted exclusively in the U.S. under FDA supervision.
  • Suven emphasizes innovation and commitment to advancing treatment options for patients with Major Depressive Disorder (MDD).

You might like these

Nepal Exports Power to Bangladesh via India's Grid

RBI Survey: Loan Demand to Stay Strong

Strides, Kenox Partner for Nasal Sprays

China's May Economy: Retail Rises, Tariffs Weigh

Birla vs. Asian Paints: Antitrust Battle

India-US Trade Pact Progress: Key Details & Outcomes

SEBI Proposal Shakes AMC Stocks

News that matters the most ⚡